



# broaden

## STUDY

### **About Familial Partial Lipodystrophy (FPL) and volanesorsen**

Apolipoprotein C-III (apoC-III) is a protein found in blood that functions as a key regulator of triglyceride levels. Patients with Familial Partial Lipodystrophy (FPL) have higher levels of apoC-III, elevated triglycerides and severe insulin resistance. Volanesorsen is an investigational new drug designed to reduce the amount of apoC-III in the bloodstream. It is thought that decreasing the amount of apoC-III could help lower the amount of triglycerides in the blood in patients with FPL. This could in turn help improve insulin sensitivity and reduce select symptoms. Researchers are conducting a Phase 2/3 clinical trial for volanesorsen in the treatment of FPL that is currently enrolling patients.

### **About the BROADEN Study**

The BROADEN Study is a randomized, placebo controlled, double blind, clinical trial being conducted by Akcea Therapeutics. The main purpose of the BROADEN Study is to assess the effects of volanesorsen on triglyceride levels and other metabolic derangements in people with FPL.

### **Who can take part?**

The BROADEN Study is open to men or women ( $\geq 18$ ) with a diagnosis of FPL, type 2 diabetes and hypertriglyceridemia. Certain other inclusion and exclusion criteria apply.

### **Important information for participants in the BROADEN Study**

Participants in the BROADEN Study will be administered volanesorsen via subcutaneous injection once weekly for 52 weeks. Patients will then be eligible to participate in an open-label extension study. Following the dosing period, patients will participate in a 13-week period of follow up involving blood tests and other measurements to assess the effects of treatment with volanesorsen.



*A subsidiary of Ionis Pharmaceuticals, Inc.*

55 Cambridge Parkway Suite 100  
Cambridge, MA 02142  
Tel: 617-207-0202  
info@akceatx.com

**Additional information about the BROADEN Study is available at <https://clinicaltrials.gov/ct2/show/NCT02527343>. For information about clinical study sites, please e-mail [research@akceatx.com](mailto:research@akceatx.com).**